ID

17785

Descripción

NCT00334568/ GSK-AVA100193: M.Alzheimer GSK A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-raging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer´s disease. Medicine: rosiglitazone, Condition: Alzheimer´s Disease, Phase: 2, Clinical Study ID: AVA 100193, Sponsor: GSK. This ODM contains the Running Logs.

Palabras clave

  1. 3/10/16 3/10/16 -
  2. 9/12/16 9/12/16 -
Subido en

3 de octubre de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Running Logs

NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Running Logs

General Information
Descripción

General Information

Protocol Identifier: AVA100193
Descripción

Protocol Identifier

Tipo de datos

boolean

Subject Identifier
Descripción

Subject Identifier

Tipo de datos

integer

Were any concomitant medications taken by the subject during the study?
Descripción

If yes, record each medication on a separate line using Trade Names where possible. If the medication is related to an Adverse Event or Serious Adverse Event, details should be expressed using the same terminology.

Tipo de datos

boolean

Did the subject experience any non-serious adverse events during the study?
Descripción

If yes, record details below.

Tipo de datos

boolean

Concomitant Medications
Descripción

Concomitant Medications

Drug Name (Trade Name preferred) (e.g. Aspirin) If `YES`, record each medication on a seperate line using Trade Names where possible. If the medication is related to an Adverse Event or Serious Adverse Event, details should be expressed using the same terminology.
Descripción

Drug Name

Tipo de datos

text

Alias
UMLS CUI [1]
C0013227
Total Daily Dose (e.g 400)
Descripción

Total Daily Dose

Tipo de datos

integer

Units (e.g mg)
Descripción

Units

Tipo de datos

text

Alias
UMLS CUI [1]
C1519795
Route (e.g PO)
Descripción

Route

Tipo de datos

text

Reason for Medication (e.g. Headache) If `YES`, record each medication on a seperate line using Trade Names where possible. If the medication is related to an Adverse Event or Serious Adverse Event, details should be expressed using the same terminology.
Descripción

Reason for Medication

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0013227
Start Date
Descripción

Start Date

Tipo de datos

date

Stop Date
Descripción

Stop Date

Tipo de datos

date

Ongoing Medication?
Descripción

Ongoing Medication

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2826666
Non-Serious Adverse Events (AE)
Descripción

Non-Serious Adverse Events (AE)

Event (Diagnosis Only - if known - Otherwise Sign/Symptom)
Descripción

Event

Tipo de datos

text

Start Date
Descripción

Start Date

Tipo de datos

date

Outcome
Descripción

Outcome

Tipo de datos

text

End Date
Descripción

End Date

Tipo de datos

date

Maximum Intensity
Descripción

Maximum Intensity

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C0518690
UMLS CUI [1,2]
C0877248
Actions Taken with Investigational Product(s) as a Result of the Non-Serious AE
Descripción

Actions Taken with Investigational Product(s) as a Result of the Non-Serious AE

Tipo de datos

text

Did the subject withdraw from study as a result of this AE?
Descripción

Withdrawal

Tipo de datos

boolean

Is there a reasonable possibility that the AE may have been caused by the investigational product?
Descripción

Relationship to Investigational Product(s)

Tipo de datos

boolean

Serious Adverse Event (SAE) - General Information
Descripción

Serious Adverse Event (SAE) - General Information

Protocol Identifier: AVA100193
Descripción

Protocol Identifier

Tipo de datos

boolean

Subject Identifier
Descripción

Subject Identifier

Tipo de datos

integer

Centre/Investigation Number
Descripción

Centre/Investigation Number

Tipo de datos

integer

Randomization Number
Descripción

Randomization Number

Tipo de datos

integer

Did the subject experience a serious adverse event during the study? If Yes, record details below.
Descripción

SAE

Tipo de datos

boolean

Serious Adverse Event (SAE) - Section I
Descripción

Serious Adverse Event (SAE) - Section I

Event (diagnosis only, otherwise sign/symptom)
Descripción

Event

Tipo de datos

text

Alias
UMLS CUI [1]
C0877248
Start Date
Descripción

Start Date

Tipo de datos

date

Outcome
Descripción

Outcome

Tipo de datos

integer

End Date
Descripción

If fatal, record date of death.

Tipo de datos

date

Maximum Intensity
Descripción

Maximum Intensity

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C0518690
UMLS CUI [1,2]
C0877248
Action Taken with Investigational Product as a Result of the SAE Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occured. Dose interrupted = Administration of one or more investigational product(s) was stopped temporarily but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre- or post-dosing). Note: If this is a Serious Adverse Event (SAE), do not complete this form, go to the SAE section and complete the SAE form.
Descripción

Action Taken with Investigational Product as a Result of the SAE

Tipo de datos

integer

Did the subject withdraw from study as a result of this SAE?
Descripción

Withdrawal

Tipo de datos

boolean

Is there a reasonable possibility the SAE may have been caused by the investigational product?
Descripción

Relationship to Investigational Product

Tipo de datos

boolean

IF fatal, was a post-mortem/autopsy perfomed? (If `Yes`, summarise findings in Section 11 Narrative Remarks on this SAE form.)
Descripción

Autopsy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004398
Serious Adverse Event (SAE) - Section II
Descripción

Serious Adverse Event (SAE) - Section II

Specify reasons for considering this a SAE
Descripción

Specification

Tipo de datos

text

If other, please specify
Descripción

Specification of Other

Tipo de datos

text

Serious Adverse Event (SAE) - Section III Demography Data
Descripción

Serious Adverse Event (SAE) - Section III Demography Data

Date of birth
Descripción

Date of birth

Tipo de datos

date

Sex
Descripción

Sex

Tipo de datos

text

Alias
UMLS CUI [1]
C0079399
Weight
Descripción

Weight

Tipo de datos

float

Unidades de medida
  • kg
Alias
UMLS CUI [1]
C0005910
kg
Serious Adverse Event (SAE) - Section IV
Descripción

Serious Adverse Event (SAE) - Section IV

If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
Descripción

If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?

Tipo de datos

text

Serious Adverse Event (SAE) - Section V
Descripción

Serious Adverse Event (SAE) - Section V

Possible Causes of SAE Other Than Investigational Product(s)
Descripción

Possible Causes of SAE Other Than Investigational Product(s)

Tipo de datos

text

If Other, please specify
Descripción

Specification of Other

Tipo de datos

text

Serious Adverse Event (SAE) - Section VI
Descripción

Serious Adverse Event (SAE) - Section VI

Specify any RELEVANT past or current medical disorder, allergies, surgeries, etc. that can help explain the SAE:
Descripción

Medical Condition

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1519255
Date of onset
Descripción

Date of onset

Tipo de datos

date

Alias
UMLS CUI [1]
C0574845
Condition Present at Time of the SAE?
Descripción

Current Condition while SAE

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3827351
UMLS CUI [1,2]
C1519255
If No, Date of Last Occurrence
Descripción

If No, Date of Last Occurrence

Tipo de datos

date

Serious Adverse Event (SAE) - Section VII
Descripción

Serious Adverse Event (SAE) - Section VII

Other RELEVANT Risk Factors
Descripción

Other RELEVANT Risk Factors

Tipo de datos

text

Serious Adverse Event (SAE) - Section VIII - Relevant Concomitant Medications
Descripción

Serious Adverse Event (SAE) - Section VIII - Relevant Concomitant Medications

Drug Name (Trade Name preferred) (e.g. Zantac)
Descripción

Drug Name

Tipo de datos

text

Alias
UMLS CUI [1]
C2360065
Dose (e.g 150)
Descripción

Dose (e.g 150)

Tipo de datos

integer

Unit (e.g ml)
Descripción

Unit (e.g ml)

Tipo de datos

text

Frequency (e.g BID)
Descripción

Frequency (e.g BID)

Tipo de datos

text

Route (e.g PO)
Descripción

Route (e.g PO)

Tipo de datos

text

Taken Prior to Study?
Descripción

Taken Prior to Study?

Tipo de datos

boolean

Start Date
Descripción

Start Date

Tipo de datos

date

Stop Date
Descripción

Stop Date

Tipo de datos

date

Ongoing Medication?
Descripción

Ongoing Medication

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2826666
Reason for Medication (e.g. Gastric Ulcer)
Descripción

Reason for Medication

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0013227
Serious Adverse Event (SAE) - Section IX
Descripción

Serious Adverse Event (SAE) - Section IX

Details of Investigational Product(s)
Descripción

Details of Investigational Product(s)

Tipo de datos

text

Was randomisation code broken at investigational site?
Descripción

Was randomisation code broken at investigational site?

Tipo de datos

text

Serious Adverse Event (SAE) - Section X
Descripción

Serious Adverse Event (SAE) - Section X

Details of RELEVANT Assessments
Descripción

Details of RELEVANT Assessments

Tipo de datos

text

Serious Adverse Event (SAE) - Section XI
Descripción

Serious Adverse Event (SAE) - Section XI

Narrative Remarks (provide a brief narrative description of the SAE and details of treatment given)
Descripción

Narrative Remarks

Tipo de datos

text

Investigator´s signature
Descripción

Investigator´s signature

Tipo de datos

text

Investigator´s name (print)
Descripción

Investigator´s name (print)

Tipo de datos

text

Date
Descripción

Date

Tipo de datos

date

Similar models

NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Running Logs

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
General Information
Protocol Identifier
Item
Protocol Identifier: AVA100193
boolean
Subject Identifier
Item
Subject Identifier
integer
Concomitant Medications
Item
Were any concomitant medications taken by the subject during the study?
boolean
Non-Serious Adverse Events
Item
Did the subject experience any non-serious adverse events during the study?
boolean
Item Group
Concomitant Medications
Drug Name
Item
Drug Name (Trade Name preferred) (e.g. Aspirin) If `YES`, record each medication on a seperate line using Trade Names where possible. If the medication is related to an Adverse Event or Serious Adverse Event, details should be expressed using the same terminology.
text
C0013227 (UMLS CUI [1])
Total Daily Dose
Item
Total Daily Dose (e.g 400)
integer
Units
Item
Units (e.g mg)
text
C1519795 (UMLS CUI [1])
Route
Item
Route (e.g PO)
text
Reason for Medication
Item
Reason for Medication (e.g. Headache) If `YES`, record each medication on a seperate line using Trade Names where possible. If the medication is related to an Adverse Event or Serious Adverse Event, details should be expressed using the same terminology.
text
C0392360 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
Start Date
Item
Start Date
date
Stop Date
Item
Stop Date
date
Ongoing Medication
Item
Ongoing Medication?
boolean
C2826666 (UMLS CUI [1])
Item Group
Non-Serious Adverse Events (AE)
Event
Item
Event (Diagnosis Only - if known - Otherwise Sign/Symptom)
text
Start Date
Item
Start Date
date
Item
Outcome
text
Code List
Outcome
CL Item
Recovered/Resolved (1)
CL Item
Recovering/Resolving (2)
CL Item
Not recovered/Not resolved (3)
CL Item
Recovered/Resolved with sequelae (4)
End Date
Item
End Date
date
Item
Maximum Intensity
integer
C0518690 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
Code List
Maximum Intensity
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
CL Item
Not applicable (X)
Item
Actions Taken with Investigational Product(s) as a Result of the Non-Serious AE
text
Code List
Actions Taken with Investigational Product(s) as a Result of the Non-Serious AE
CL Item
Investigational Product(s) withdrawn  (1)
CL Item
Dose reduced (2)
CL Item
Dose increased (3)
CL Item
Dose not changed  (4)
CL Item
Dose interrupted (5)
CL Item
Not applicable (X)
Withdrawal
Item
Did the subject withdraw from study as a result of this AE?
boolean
Relationship to Investigational Product(s)
Item
Is there a reasonable possibility that the AE may have been caused by the investigational product?
boolean
Item Group
Serious Adverse Event (SAE) - General Information
Protocol Identifier
Item
Protocol Identifier: AVA100193
boolean
Subject Identifier
Item
Subject Identifier
integer
Centre/Investigation Number
Item
Centre/Investigation Number
integer
Randomization Number
Item
Randomization Number
integer
SAE
Item
Did the subject experience a serious adverse event during the study? If Yes, record details below.
boolean
Item Group
Serious Adverse Event (SAE) - Section I
Event
Item
Event (diagnosis only, otherwise sign/symptom)
text
C0877248 (UMLS CUI [1])
Start Date
Item
Start Date
date
Item
Outcome
integer
Code List
Outcome
CL Item
Recovered/Resolved (1)
CL Item
Recovering/Resolving (2)
CL Item
Not recovered/Not resolved (3)
CL Item
Recovered/Resolved with sequelae (4)
CL Item
Fatal (5)
End Date
Item
End Date
date
Item
Maximum Intensity
integer
C0518690 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
Code List
Maximum Intensity
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
CL Item
Not applicable (X)
Item
Action Taken with Investigational Product as a Result of the SAE Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occured. Dose interrupted = Administration of one or more investigational product(s) was stopped temporarily but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre- or post-dosing). Note: If this is a Serious Adverse Event (SAE), do not complete this form, go to the SAE section and complete the SAE form.
integer
Code List
Action Taken with Investigational Product as a Result of the SAE Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occured. Dose interrupted = Administration of one or more investigational product(s) was stopped temporarily but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre- or post-dosing). Note: If this is a Serious Adverse Event (SAE), do not complete this form, go to the SAE section and complete the SAE form.
CL Item
Investigational product(s) withdrawn  (1)
CL Item
Dose reduced (2)
CL Item
Dose increased (3)
CL Item
Dose not changed (4)
CL Item
Dose interrupted (5)
CL Item
Not applicable (6)
Withdrawal
Item
Did the subject withdraw from study as a result of this SAE?
boolean
Relationship to Investigational Product
Item
Is there a reasonable possibility the SAE may have been caused by the investigational product?
boolean
Autopsy
Item
IF fatal, was a post-mortem/autopsy perfomed? (If `Yes`, summarise findings in Section 11 Narrative Remarks on this SAE form.)
boolean
C0004398 (UMLS CUI [1])
Item Group
Serious Adverse Event (SAE) - Section II
Item
Specify reasons for considering this a SAE
text
Code List
Specify reasons for considering this a SAE
CL Item
Results in death (1)
CL Item
Is life-threatening (2)
CL Item
Requires hospitalization or prolongation of existing hospitalization  (3)
CL Item
Results in disability/Incapacity (4)
CL Item
Congenital anomaly/birth defect (5)
CL Item
Other (specify) (6)
Specification of Other
Item
If other, please specify
text
Item Group
Serious Adverse Event (SAE) - Section III Demography Data
Date of birth
Item
Date of birth
date
Item
Sex
text
C0079399 (UMLS CUI [1])
Code List
Sex
CL Item
Male (1)
CL Item
Female (2)
Weight
Item
Weight
float
C0005910 (UMLS CUI [1])
Item Group
Serious Adverse Event (SAE) - Section IV
Item
If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
text
Code List
If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
CL Item
Yes (1)
CL Item
No (2)
CL Item
Unknown at this time (3)
CL Item
Not applicable (4)
Item Group
Serious Adverse Event (SAE) - Section V
Item
Possible Causes of SAE Other Than Investigational Product(s)
text
Code List
Possible Causes of SAE Other Than Investigational Product(s)
CL Item
Disease under study (1)
CL Item
Medical condition(s) (2)
CL Item
Lack of efficacy (3)
CL Item
Withdrawal of investigational product(s) (4)
CL Item
Concomitant medication (5)
CL Item
Activity related to study participation  (6)
CL Item
Other (specify) (7)
Specification of Other
Item
If Other, please specify
text
Item Group
Serious Adverse Event (SAE) - Section VI
Medical Condition
Item
Specify any RELEVANT past or current medical disorder, allergies, surgeries, etc. that can help explain the SAE:
text
C0012634 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Date of onset
Item
Date of onset
date
C0574845 (UMLS CUI [1])
Current Condition while SAE
Item
Condition Present at Time of the SAE?
boolean
C3827351 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
If No, Date of Last Occurrence
Item
If No, Date of Last Occurrence
date
Item Group
Serious Adverse Event (SAE) - Section VII
Other RELEVANT Risk Factors
Item
Other RELEVANT Risk Factors
text
Item Group
Serious Adverse Event (SAE) - Section VIII - Relevant Concomitant Medications
Drug Name
Item
Drug Name (Trade Name preferred) (e.g. Zantac)
text
C2360065 (UMLS CUI [1])
Dose (e.g 150)
Item
Dose (e.g 150)
integer
Unit (e.g ml)
Item
Unit (e.g ml)
text
Frequency (e.g BID)
Item
Frequency (e.g BID)
text
Route (e.g PO)
Item
Route (e.g PO)
text
Taken Prior to Study?
Item
Taken Prior to Study?
boolean
Start Date
Item
Start Date
date
Stop Date
Item
Stop Date
date
Ongoing Medication
Item
Ongoing Medication?
boolean
C2826666 (UMLS CUI [1])
Reason for Medication
Item
Reason for Medication (e.g. Gastric Ulcer)
text
C0392360 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
Item Group
Serious Adverse Event (SAE) - Section IX
Details of Investigational Product(s)
Item
Details of Investigational Product(s)
text
Item
Was randomisation code broken at investigational site?
text
Code List
Was randomisation code broken at investigational site?
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not applicable (3)
Item Group
Serious Adverse Event (SAE) - Section X
Details of RELEVANT Assessments
Item
Details of RELEVANT Assessments
text
Item Group
Serious Adverse Event (SAE) - Section XI
Narrative Remarks
Item
Narrative Remarks (provide a brief narrative description of the SAE and details of treatment given)
text
Investigator´s signature
Item
Investigator´s signature
text
Investigator´s name (print)
Item
Investigator´s name (print)
text
Date
Item
Date
date

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial